Which Is The Better Pick For Your Portfolio: GlaxoSmithKline plc Or AstraZeneca plc?

Should you chose GlaxoSmithKline (LON: GSK) or AstraZeneca (LON: AZN) for your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) are similar businesses, but if you could only pick one then choosing between the two is difficult.

It really comes down to your personal investment goals — are you looking for income or growth?

Income pick

Glaxo is the income play of the two pharma giants.  The company’s shares currently support a dividend yield of 5.5%, and management has made a commitment to maintaining the payout at its present level until 2017. 

Unfortunately, Glaxo’s management has also stated that the dividend payout won’t grow over the next three years, which is disappointing. Still, there’s scope for serious payout growth after 2017. 

Room for growth

The next three years will be a transitional period for Glaxo. The company expects 2015 core earnings per share to decline at a percentage rate “in the high teens” as sales of key drugs continue to fall.

However, new treatments will start to work their way through the company’s treatment pipeline by 2016. These new products, combined with Glaxo’s drive to cut costs by £3bn per annum by 2017, will lead to slow and steady earnings growth. 

Glaxo’s management believes that group’s revenue will grow at a low-to-mid single digit percentage per annum from 2016 to 2020. During the same period, core earnings per share are expected to expand at a rate in the mid-to-high single digits. 

City analysts believe that Glaxo’s earnings per share will fall by 11% this year before rebounding by 7% during 2016.

According to my figures, assuming a 7% per annum growth rate through to 2020, Glaxo is on track to earn 111p per share for full-year 2020. This indicates that Glaxo is trading at a 2020 P/E of 13.2. 

Exciting prospects 

Astra, on the other hand, is expecting to grow at a much faster rate than Glaxo over the next five years. 

Astra currently has 72 new cancer treatments under development, 31 of which are immuno-oncology drugs. 13 immuno-oncology drug trials are under way, with a further 16 planned at the end of November last year.

And it’s this wave of new treatments that has given Astra’s management the confidence to state that revenues will hit $45bn by 2023. 

According to my figures, which are based on Astra’s historic profit margins, on revenue of $45bn the company could report a net profit of $9bn, around £5.6bn. This translates into earnings per share of £4.43.

So, based on these figures, Astra is currently trading at a 2023 P/E of 10. 

Extra income 

Astra is set to grow rapidly over the next decade, but the company also supports a dividend yield of 4% at present. The payout is covered 1.5 times by earnings per share and isn’t expected to grow over the next few years. 

Still, a yield of 4% is above the market average of 3.4%. 

The bottom line

All in all, I’d argue that the choice is simple. If you’re looking for income, Glaxo is the better pick. However, if you’re looking for a growth play, Astra could be the best choice.

That being said, Astra does support a dividend yield of 4%, which is above the market average and complements the company’s long-term growth profile extremely well. If income investors are willing to accept a the reduced level of income, in exchange for growth potential, Astra could be the best bet. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Can the Rolls-Royce share price hit £13 in the coming year?

After a stunning couple of years for the Rolls-Royce share price, can it keep up its recent momentum? This writer…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s how a £20k ISA could produce £1,580 of passive income in the next year

A Stocks and Shares ISA stuffed with dividend shares can be a lucrative source of passive income. Christopher Ruane explains…

Read more »

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »